Title :

Comparison of response evaluation criteria in solid tumours and choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis

Author(s) :

Taieb, Sophie [Auteur]
Saada-Bouzid, Esma [Auteur]
Tresch-Bruneel, Emmanuelle [Auteur]
Ryckewaert, Thomas [Auteur]
Bompas, Emmanuelle [Auteur]
Italiano, Antoine [Auteur]
Guillemet, Cécile [Auteur]
Peugniez, Charlotte [Auteur]
Piperno-Neumann, Sophie [Auteur]
Thyss, Antoine [Auteur]
Maynou, Carlos [Auteur]
Clisant-Delaine, Stephanie [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Journal title :

European journal of cancer (Oxford, England . 1990)

Abbreviated title :

Eur. J. Cancer

Volume number :

51

Pages :

202-209

Publication date :

2015-01-01

ISSN :

0959-8049

English keyword(s) :

Trabectedin
Sarcoma
Response assessment

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: To assess the additional value of density measurement using contrast-enhancement sequences (Choi assessment) in a real-life cohort of adult soft tissue sarcoma patients treated with trabectedin. METHODS: ...
Show more >BACKGROUND: To assess the additional value of density measurement using contrast-enhancement sequences (Choi assessment) in a real-life cohort of adult soft tissue sarcoma patients treated with trabectedin. METHODS: Eligibility criteria included adults (age ⩾18) treated between 01/2007 and 12/2011, with at least two trabectedin cycles after failure or intolerance to doxorubicin/ifosfamide. Baseline and first computed tomography (CT)-scans were centrally reviewed by an experienced radiologist. RESULTS: The retrospective cohort consists of 134 (73 female) patients treated with trabectedin 1.5 mg/m(2) given as a 24-h infusion every 3 weeks. Patients received a median of five trabectedin cycles (range: 2-33) and the main cause of discontinuation was progressive disease (PD) (n = 105, 78.4%). Response Evaluation Criteria in Solid Tumours (RECIST) assessment was feasible in 128 (95.5%) patients, with Choi assessment performed in 92 (68.7%) patients, generally due to inadequate sequences or exclusive lung metastases. Concordance between both methods was fair (Kappa = 0.290). We identified five patients with false PD (i.e. PD according to RECIST but stable disease/partial response as per Choi). Univariate analysis did not identify any predictive factors for false PD. Median overall survival (OS) of patients with PD as per RECIST but stable disease/partial response (SD/PR) according to Choi was better than for patients with PD according to both RECIST and Choi (14 months versus 8 months; p = 0.052). CONCLUSIONS: Choi assessment may identify patients with false PD who achieved improved efficacy outcomes, suggesting that trabectedin may delay tumour progression even in the case of non-dimensional response. Dual size and tumour density assessment may be more suitable to evaluate responses to trabectedin in sarcoma patients as well as to improve the decision-making strategies for the continuation of trabectedin therapy.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:56:09Z